|1.||Després, Jean-Pierre: 11 articles (07/2011 - 11/2005)|
|2.||Bifulco, Maurizio: 10 articles (06/2015 - 10/2004)|
|3.||Kim, Jeongmin: 10 articles (02/2010 - 04/2008)|
|4.||Lee, Jinhwa: 10 articles (02/2010 - 04/2008)|
|5.||Lee, Sung-Han: 10 articles (02/2010 - 04/2008)|
|6.||Di Marzo, Vincenzo: 9 articles (11/2013 - 12/2002)|
|7.||Seo, Hee Jeong: 9 articles (02/2010 - 04/2008)|
|8.||Scheen, André J: 9 articles (02/2009 - 04/2005)|
|9.||Laezza, Chiara: 8 articles (06/2015 - 10/2004)|
|10.||Jung, Myung Eun: 8 articles (02/2010 - 04/2008)|
04/01/2008 - "However, given the efficacy of this treatment and the magnitude of the obesity problem, rimonabant may prove to be a valuable adjunct in targeting obesity-related cardiovascular risk factors."
05/01/2012 - "They have been explored and found to be effective as therapeutic agents for obesity and related cardiometabolic problems; however, use of rimonabant, the first marketed CB(1) receptor antagonist, has been suspended because of its anxiogenic and depressogenic side effects. "
04/01/2005 - "In humans, rimonabant appears to be effective for treatment of obesity and smoking cessation. "
05/01/2007 - "Is rimonabant a safe and effective treatment for obesity?"
06/01/2004 - "Rimonabant was shown to be safe and effective in treating the combined cardiovascular risk factors of smoking and obesity. "
|2.||Weight Loss (Weight Reduction)
01/01/2014 - "Central CB1R antagonists, notably rimonabant, induced weight loss and improved the metabolic profile in obese individuals, but were discontinued due to psychiatric side-effects. "
10/01/2009 - "Rimonabant resulted in a significantly greater benefit than placebo for all primary weight loss outcomes. "
07/01/2008 - "Weight loss from baseline to 2 years in the intention-to-treat population was significantly greater with rimonabant 20 mg (mean +/- SD: -5.5 +/- 7.7 kg; P < 0.001) and 5 mg (-2.9 +/- 6.5 kg; P = 0.002) than placebo (-1.2 +/- 6.8 kg). "
04/01/2008 - "Moreover, it has been shown that the agent rimonabant, which was first used in order to achieve weight reduction, also contributed to the significant improvement of metabolic syndrome's parameters. "
11/11/2006 - "Weight loss was significantly greater after 1 year in both rimonabant groups than in the placebo group (placebo: -1.4 kg [SD 3.6]; 5 mg/day: -2.3 kg [4.2], p=0.01 vs placebo; 20 mg/day: -5.3 kg [5.2], p<0.0001 vs placebo). "
|3.||Body Weight (Weight, Body)
02/01/2013 - "These results provide proof of principle that combination of rimonabant and a MCH1 receptor antagonist is highly effective in reducing body weight below that achieved by rimonabant and SNAP-94847 monotherapies. "
02/01/2013 - "Combining sub-threshold doses of rimonabant and SNAP-94847 produced a significantly greater loss of body weight in DIO mice compared with vehicle and monotherapies. "
02/01/2010 - "On all three diets, rimonabant treatment improved metabolic derangements and led to significantly lower body weight gain than their respective controls. "
08/01/2013 - "NESS06SM reduces body weight with an improved profile relative to SR141716A."
02/01/2011 - "In all the trials, there was a considerable reduction in body weight in subjects taking 20 mg rimonabant daily varying from 2.6 to 6.3 kg (placebo-subtracted changes). "
03/01/2012 - "Treatment with SR141716 significantly improved insulin resistance and lipid abnormalities. "
07/01/2013 - "Our data might indicate that a lower dose of rimonabant in the treatment of insulin resistance and type 2 diabetes is sufficient to administer, thus a lower incidence of the unfavorable psychiatric side effects of rimonabant are to be expected. "
01/16/2009 - "Interestingly, the rimonabant-treated adipo(-/-)ob/ob mice also exhibited significant amelioration of insulin resistance, although the degree of improvement was significantly lower as compared with that in the ob/ob mice. "
03/01/2012 - "Therefore, we examined the effect of the cannabinoid (CB)1 receptor antagonist, SR141716, on insulin resistance and diabetic nephropathy in db/db mice. "
07/01/2008 - "Rimonabant is shown in the current issue of British Journal of Pharmacology to attenuate weight gain in Zucker rats, an experimental model of insulin resistance. "
01/01/2006 - "In four randomised, double-blind clinical trials in overweight or obese adults with or without type 2 diabetes and/or dyslipidaemia, oral rimonabant 20mg once daily reduced weight and waist circumference to a significantly greater extent than placebo. "
03/01/2007 - "Rimonabant, a selective CB(1) antagonist, is a novel treatment option for obese and overweight individuals. "
08/01/2010 - "This study sought to identify the effect of drug reimbursability--a decision made in France by the National Authority for Health--on physicians' prescribing practices for a diet drug such as rimonabant, approved for obese or overweight patients with type-2 diabetes. "
11/11/2006 - "Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study."
08/23/2006 - "[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies]."
|1.||CB1 Cannabinoid Receptor (CB1 Receptor)
|9.||Cannabinoid Receptors (Cannabinoid Receptor)
|1.||Drug Therapy (Chemotherapy)
|3.||Self Administration (Administration, Self)